Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/03/2018|
|Rapid review completed||10/05/2018|
|Rapid Review outcome||A Full pharmacoeconomic assessment is recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.